Glycine Site Agonists of the NMDA Receptor: A Review

CNS Drug Reviews

Volumn 1, Issue 2, 1995, Pages 227-260

  D'Souza, Deepak Cyril ^a   Charney, Dennis ^a   Krystal, John ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dementias; D cycloserine; Glycine milacemide; Glycine site agonists; N methy D aspartate; Schizophrenia; Strychnine insensitive glycine site

Indexed keywords

EID: 84989427494     PISSN: 1080563X     EISSN: 15273458     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1995.tb00285.x     Document Type: Article

References (199)

1. Pharmacology and toxicology of cycloserine
2. 3H]MK‐801 binding to NMDA receptors solubilized from rat brain: effects of glycine site ligands, polyamines, ifenprodil and desipramine
3. A kinetic analysis of modulation of N‐methyl‐D aspartate receptors desensitization by glycine in mouse cultured hippocampal neurones
4. Kinetic analysis of antagonist action at N‐methyl‐D aspartate receptors. Two binding sites each for glutamate and glycine
5. Glycine, glycyl‐glycine and maltodextrin based oral rehydration solution
6. Behavioral studies on rats injected with L‐cycloserine and other compounds
7. Glycine regulation of the NMDA receptor‐gated ion channel in hippocampal membranes
8. Pyramidal neuron loss and “glycine site therapy”: A need for an animal model and study in late‐life depression
9. A therapeutic trial of milacemide in myoclonus and stiff person syndrome
10. 3H]catecholamlnes from rat brain
11. Effects of D‐cycloserine and (+)‐HA‐966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine‐depleted mice
12. Schizophrenia a subcortical neurotransmitter imbalance syndrome
13. Interactions of glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease
14. Glycine antagonists. Regulation of the NMDA receptor‐channel complex by the strychnine‐ insensitive glycine site
15. D‐cycloserine adjuvant therapy to conventional neuroleptic therapy in schizophrenia: an open label study
16. Metabolism of a new epileptic drug in the brain
17. Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer's type
18. D‐cycloserine, a putative cognitive enhancer, facilitates activation of the NMDA receptor‐ionophore complex in Alzheimer brain
19. Glycine action of NMDA receptors in rat hippocampal neurons
20. Non‐NMDA receptor‐mediated neuronal injury in Alzheimer's disease
21. NMDA receptors—their role in long term potentiation
22. Excitatory amino acid receptors in the vertebrate nervous system
23. Evidence of functional coupling of the NMDA and glycine recognition sites in synaptic plasma membranes
24. Serine antagonized Phencyclidine and MK‐801 induced stereotyped behaviour and ataxia
25. The physiological disposition of D‐cycloserine in the human subject
26. An open trial of glycine as an adjunct to neuroleptics in the chronic treatment of refractory schizophrenia
27. Chemistry and anatomy of excitatory amino acid systems
28. The psychotropic effects of Cycloserine: A new use for an antibiotic
29. Cycloserine as an antidepressant agent
30. Dual component NMDA receptor currents at a single central synapse
31. The NMDA positive modulator D‐cycloserine potentiates the neuroleptic activity of D1 and D2 receptor blockers in rats
32. Different action of 3‐amino‐l‐hydroxy‐2‐pyrrolione (HA‐966) and 7‐chlorkynurenic acid in the modulation of NMDA sensitive glutamate receptors
33. Frontal & left temporal glutamatergic dysfunction in schizophrenia
34. Zur Hemmung der L‐glutaminsaure and L‐dopadecarboxylase durch D‐Cycloserin und andere Isoxazolidone
35. “Glutamatergic Hypothesis” of schizophrenia‐rationale pharmacotherapy with glycine
36. Glutamatergic abnormalities in Alzheimer's disease and a rationale for clinical trials with L‐glutamate
37. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B
38. Excitotoxic mechanisms in the pathogenesis of dementias
39. Pharmacological effects of Cl‐581, a new dissociative anesthetic, in man
40. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease
41. Milacemide: Safety assessment in senile dementia of the Alzheimer's type
42. Actions of D‐cycloserine at the NMDA associated glycine receptor site in‐vivo
43. Psychiatric sequelae of phencyclidine abuse
44. 3H]Glycine uptake in rat hippocampus; kinetic analysis and autoradiographic localization
45. 3H]glycine uptake in rat forebrain: Cellular localization in the hippocampus
46. Glycine reverses antagonism of NMDA by the l‐hydroxy‐3‐aminopyrrolidone‐2 (HA‐966) but not by D‐2‐amino‐phosphonovalerate (D‐AP5) on rat cortical slices
47. Effect on memory processing by D‐cycloserine, an agonist of the NMDA/glycine receptor
48. HA‐966 antagonizes NMDA receptors through a selective interaction with the glycine receptor
49. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: Investigative and therapeutic perspectives
50. 3H]AMPA binding in postmortem human brain from psychotic subjects and controls: Increases in caudate nucleus associated with suicide
51. Glutamatergic therapy for Huntington's Chorea
52. Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine and gamma‐aminobutyric acid in vulnerable and non‐vulnerable brain regions in the rat
53. Dose‐finding trial of D‐cycloserine added to neuroleptics for negative symptoms in schizophrenia
54. Excitatory amino acids and Alzheimer's disease
55. Author's response to commentaries
56. Interactions between the glutamate and glycine recognition sites of the NMDA receptor from rat brain, as revealed from radioligand binding studies
57. Cloning, expression, and localization of a rat brain high‐affinity glycine transporter
58. Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents
59. Serum amino acid patterns and toxicity symptoms following the absorption of irrigant fluid containing glycine in transurethral prostatic surgery
60. Glutamate deficits in Alzheimer's disease
61. Region specific loss of glutamate innervation in Alzheimer's disease
62. D‐Alanine inhibits methamphetamine‐induced hyper‐activity in rats
63. An open trial with glycine in schizophrenia
64. Competitive antagonists and partial agonists at the glycine modulatory site of the mouse NMDA receptor
65. Cloned glutamate receptors
66. N‐methyl‐D‐aspartate recognition site ligand modulate activity at the coupled glycine recognition site
67. D‐cycloserine: A ligand for the NMDA coupled glycine receptor has partial agonist characteristics
68. 1‐Amino‐1‐carboxylate (ACBC): A specific antagonist of the NMDA receptor coupled glycine receptor
69. Double–blind study of milacemide in hospitalized therapy‐resistant patients with epilepsy
70. Competitive antagonism of glycine at the NMDA receptor
71. NMDA‐associated glycine binding sites increases in schizophrenic brains
72. Increases in strychnine‐insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis
73. Mode of action, biotransformation and pharmacokinetics of antituberculosis drugs in animals and man
74. Amelioration of negative symptoms in schizophrenia by glycine
75. Recent advances in the PCP model of schizophrenia
76. Glycine potentiates the NMDA response in cultured mouse neurons
77. Effects of NMDA modulation of scopolamine dementia
78. The glycine site of the NMDA receptor—five years on
79. Psychological side‐effects induced by cycloserine in the treatment of tuberculosis
80. Assymetric loss of glutamate receptor subtype in left hippocampus in schizophrenia (letter)
81. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post‐mortem
82. Glycine stimulates growth hormone release in man
83. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
84. The glycine site of the N‐methyl‐D‐aspartate receptor channel: Differences between the binding of HA‐966 and of 7‐chlorkynurenic acid
85. Requirement for glycine in activation of NMDA receptors expressed in Xenopus oocytes
86. 3H]MK‐801 binding sites in the postmortem brain regions of schizophrenic patients
87. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychomimetic, perceptual, cognitive and neuroendocrine responses
88. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
89. 3H]Amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionic acid binding to human cerebral cortical membranes: Minimal changes in postmortem brains of chronic schizophrenics
90. D‐cycloserine: Agonist turned antagonist
91. 2+] response to NMDA application investigated with microdialysis of rabbit hippocampus in vivo
92. In vivo determination of extracellular concentrations of amino acids in the rat hippocampus. A method based on brain microdialysis and computerized analysis
93. Glycine decreases desensitization of NMDA receptors expressed in Xenopus oocytes and is required for NMDA responses
94. Requirements for high affinity binding of glycine analogs to the glycine site of the NMDA receptor complex
95. Psychiatric and neurological reactions to cycloserine in the treatment of tuberculosis
96. Pharmacotherapies for alcoholism: promising new agents and clinical issues
97. Cloning and expression of a spinal cord‐specific and brain‐specific glycine transporter with novel structural features
98. Noncompetitive excitatory amino acid antagonists
99. Ethanol inhibits NMDA‐activated ion current in hippocampal neurons
100. Ethanol inhibits excitotoxicity in cerebral cortical cultures
101. Model psychoses and schizophrenia
102. 1‐Amino‐cyclopropane carboxylic acid: A potent and selective ligand of the glycine modulatory site of the NMDA receptor complex
103. The physiology of excitatory amino acids in the vertebrate central nervous system
104. Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine
105. Glutamate: Its role in learning, memory and the aging brain
106. Structural requirements for activation of the glycine coagonist site of the NMDA receptors expressed in Xenopus oocytes
107. Evidence for site specific ethanol actions in the CNS
108. A high performance liquid chromatographic assay for 1‐Aminocyclopropanecarboxylic acid from plasma and brain
109. 3H]Glycine recognition site as a modulatory site of the N‐methyl‐D‐aspartate receptor complex
110. Two classes of NMDA recognition sites: Differential distribution and differential regulation by glycine
111. Glycine modulation of NMDA receptors: Autoradiographic studies
112. Regional variations in NMDA receptor properties
113. A pilot study of Cycloserine toxicity
114. Absorption, distribution and excretion of cycloserine in man
115. The current excitement in long‐term potentiation
116. 3H]kainic acid binding in the prefrontal cortex in schizophrenia
117. Phase II study to evaluate the efficacy and safety of milacemide (CP 1552S) in the treatment of complex‐partial seizures in adult patients
118. 3H]glycine to synaptic membranes in rat brain, treated with Triton X‐100
119. Brain uptake of radiolabelled amino acids, amines and hexoses after arterial injection
120. Excitatory amino acids and neuropsychiatric disorders
121. The anticonvulsant activity of D‐cycloserine is specific for tonic convulsions
122. Movement of glycine across the blood brain barrier
123. L‐cycloserine: Behavioral and biochemical effects after single and repeated administration to rats, mice and cats
124. Growth hormone release by glycine injected intravenously in 22 healthy immature children
125. Glycine in the treatment of schizophrenia: Theory and preliminary results
126. 3H]MK‐801 binding in Alzheimer's disease
127. Loss of glycine‐dependent radioligand binding to the NMDA‐phencyclidine receptor complex in patients with Alzheimer's disease
128. Stereoselectivity for the (R)‐enantiomer of HA‐966 (1‐hydroxy‐3‐aminopyrrolidone‐2) at the glycine site of the NMDA receptor complex
129. The neurobiology of Huntington's disease
130. Acute but not chronic activation of the NMDA coupled glycine receptor with D‐cycloserine facilitates learning and retention
131. Glycine site‐directed agonists reverse the actions of ethanol at the NMDA receptor
132. Neuropharmacological characterization of 1‐Aminocyclopropane‐1‐carboxylate and 1‐Aminocyclobutane‐1‐carboxylate, ligands of the NMDA‐associated glycine receptor
133. NMDA receptors and learning—a framework for classifying some recent studies
134. 3H]L‐689,560 binding to the glycine site of the glu‐tamate/NMDA receptor in the brain in Huntington's disease
135. Ethylmalonic/adipic aciduria: Effects of medium chain triglycerides, carnitine and glycine on urinary excretion of organic acids, acylcarnitines, and acylglycines
136. Pharmacology and toxicology of cycloserine
137. Antituberculosis drugs
138. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open label pilot study
139. An NMDA intervention strategy in schizophrenia with low dose milacemide
140. Acute and subacute central nervous system affects of milacemide in elderly people. Double‐blind placebo‐controlled quantitative electroencephalographic and psychometric investigations
141. The anticonvulsant properties in the mouse of the glycine/NMDA receptor antagonist, L‐687,414
142. D‐cycloserine reverses the working memory impairment of hippocampal‐lesioned rats in a spatial learning task
143. Serine hydroxymethyl transferase
144. The effects of milacemide on item and source memory
145. Glycine prodrug facilitates word retrieval in humans
146. Milacemide effects on the temporal inter‐relationship of amino acids and mono‐amine metabolites in rat cerebrospinal fluid
147. Effect of milacemide on extracellular and tissue concentrations of dopamine and 5‐hydroxytryptamine in rat frontal cortex
148. Inhibition patterns by analogs indicates the presence of ten or more transport systems for amino acids in brain cells
149. Evidence of glutamatergic deficiency in schizophrenia
150. Deficient NMDA‐mediated glutamate release from synap‐tosomes of schizophrenics
151. d‐Cycloserine therapy of psychosis by symptom provocation
152. D‐cycloserine, a modulator of the NMDA receptor, improves spatial learning in rats treated with muscarinic antagonist
153. Modulation of seizure susceptibility in mouse by the strychnine‐insensitive glycine recognition site of the NMDA receptor/channel complex
154. Chronic treatment with 1‐Aminocyclopropanecar‐boxylic acid desensitizes behavioral responses to compounds acting at the NMDA receptor complex
155. Cloning and expression of a glycine transporter reveal co‐localization with NMDA receptors
156. 3H]vpiperidinebinding
157. A current appraisal of cycloserine
158. Enhancement of NMDA‐mediated transmission in schizophrenia
159. Stereoselective inhibition by D‐ and L‐alanine of phencyclidine‐induced locomotor stimulation in the rat
160. Stereoselective inhibition by enantiomers of and alanine of phencyclidine‐induced hyperactivity, stereotype and ataxia in the rat
161. Experimental pharmacology and toxicology of antituberculosis drugs
162. In vivo modulation of NMDA receptor‐dependent long‐term potentiation by the glycine modulatory site
163. Glycine modulation of the NMDA receptor/channel complex
164. Hippocampus‐dependent learning facilitated by a monoclonal antibody to D‐cycloserine
165. Glycine modulation of the NMDA receptor/channel complex
166. Glycine is a coagonist at the NMDA receptor/channel complex
167. Neurotransmitters, receptors and neuropeptides in post‐mortem brains of chronic schizophrenic patients
168. Excitatory amino acids: Implications for psychiatric disorders research
169. Antagonism of phencyclidine‐induced hyperactivity by glycine in mice
170. Elevation of cerebral level of non‐essential amino acid in vivo by administration of large doses
171. 1‐Aminocyclopropanecarboxylic acid, a ligand of the strychnine‐insensitive glycine binding site exhibits anxiolytic properties
172. 1‐Aminocyclopropane‐carboxylic acid exhibits antidepressant and anxiolytic actions in animal models
173. Therapeutic trial with glycine in myoclonus
174. The glutamatergic basis of human alcoholism
175. Anticonvulsant activity of milacemide
176. Differential behavioral and biochemical effects on the central nervous system of cycloserine isomers
177. Modulation of N‐methyl‐D aspartate (NMDA) receptors desensitization by glycine in mouse cultured hippocampal neurones
178. Excitatory amino acid transmitters
179. D‐cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA expressed Xenopus oocytes
180. Pharmacological characteristics of cyclic analogues of glycine at the NMDA receptor associated glycine site
181. Glycine therapy for schizophrenia
182. Effect of the glycine/NMDA receptor partial agonist, D‐cycloserine, on seizure threshold and some pharmacodynamic effects of MK‐801 in mice
183. 3H]glycine transport sites in the cerebellar cortex
184. Effect of the glycine/NMDA receptor partial agonist, D‐cycloserine, on seizure threshold and some pharmacodynamic effects of MK‐801 in mice
185. Sites for the antagonism on the NMDA receptor channel complex
186. Effect of L‐cycloserine on brain GABA metabolism
187. Cloning, expression and modulation of a mouse NMDA receptor subunit
188. Differential profiles of binding of a radiolabelled agonist and antagonist at a glycine recognition domain on the N‐methyl‐D‐aspartate receptor ionophore complex in rat brain
189. Milacemide: A neuropsychotropic glycine prodrug with serotonin potentiating activity
190. NMDA receptor losses in the putamen from patients with Huntington's disease
191. Facilitated transport of amino acids through the blood brain barrier of the dog studied in the single capillary circulation
192. Characteristics and adaptive regulation of glycine transport in cultured glial cells